Introduction: Patient safety begins long before a drug product reaches the clinic — it begins with the container that holds […]
Extractables and Leachables (E&L) Testing for Container Closure Integrity Programs Read More »
Introduction: Carmustine PLGA characterization sits at the intersection of polymer science, oncology pharmacology, and regulatory compliance — making it one
Introduction: Aripiprazole lauroxil (Aristada®) is a PLGA-based long-acting injectable antipsychotic that differs fundamentally from other LAI microsphere products. As discussed
Introduction: Goserelin PLGA implant characterization is one of the most technically demanding challenges in long-acting parenteral development — and also
Introduction: Insulin analog characterization for generic ANDA is one of the most scientifically demanding challenges in the follow-on biologics space.
Introduction: Higher-order structure characterization of therapeutic peptides is no longer optional science — it is a regulatory and scientific imperative.
Introduction: Naltrexone PLGA microsphere burst release is one of the most technically demanding problems in long-acting injectable (LAI) formulation science.
Naltrexone PLGA Microsphere Case Study: Controlling Burst Release Through Polymer Design Read More »
Introduction: Extractables and Leachables Testing for Ophthalmic Drug Products is not simply a regulatory checkbox — it is a critical
Introduction: Nitrosamine impurities are among the most scrutinized safety concerns in modern pharmaceutical development, and no NDA or BLA submission
Nitrosamine Risk Assessment and Testing Services for NDA and BLA Submissions Read More »
Summary: 1: Introduction: Buprenorphine PLGA Depot Characterization is critical for the development of long-acting injectable formulations intended for opioid dependence
